Vanguard Capital Management
BCDA icon

Vanguard Capital Management’s BioCardia BCDA Stock Holding History

Vanguard Capital Management’s Portfolio BCDA Stock Details BCDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Hold
124,591
– – ﹤0.01% 3840
2026
Q1 		$151K Buy
+124,591
New +$156K ﹤0.01% 3828

Other funds holding BCDA

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
PP
Pingora Partners Wilson, Wyoming $171M AUM 60.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management's BCDA Position: Q2 2026 in Review

Vanguard Capital Management held its BioCardia (BCDA) position steady in Q2 2026 at 124,591 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #3840.

Vanguard Capital Management first reported a position in BCDA in Q1 2026 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold BCDA as of Q2 2026.

  • Vanguard Capital Management held 124,591 shares of BioCardia worth $154K as of Q2 2026.
  • Vanguard Capital Management left its BioCardia share count unchanged in Q2 2026.
  • BioCardia made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3840 holding.
  • Vanguard Capital Management first reported a position in BioCardia in Q1 2026 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held BioCardia as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.